- Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID.
- RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients.
- In view of the other vaccine plays, it is important to make an assessment of the company's position.
- Disposal of stake in Sonnet Bio and additional capital available through equity participation by main shareholder GEM puts the company in a strong financial position to carry out clinical trials.
- Given, the specific use of its potential drug, the company is a buy. This follows a risk analysis.
For further details see:
Relief Therapeutics: COVID Treatment For Emergencies